Carbenicillin

Summary

Carbenicillin (CHEMBL1214) is an approved small-molecule antibacterial drug (ATC J01CA03); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CA03
• Indications: 2 conditions
• Chemistry: 378.4 Da · C17H18N2O6S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1214
Name	Carbenicillin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	20824
ChEBI	CHEBI:3393
ATC	J01CA03
Molecular formula	C17H18N2O6S
Molecular weight	378.4
InChIKey	FPPNZSSZRUTDAP-UWFZAAFLSA-N

SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C

IUPAC name: (2S,5R,6R)-6-[(2-carboxy-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

ChEBI definition: A penicillin antibiotic having a 6β-2-carboxy-2-phenylacetamido side-chain.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Carbenicilina, Carbenicillin, Carbenicilline, carbenicillin, CARBENICILLINE, CARBENICILLIN, BAY-B-5369

Parent form; salt/anhydrous children: CHEMBL606260, CHEMBL2105992

Patent coverage: 18,064 distinct patent families (63,952 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).